Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo.

Resveratrol, a polyphenol found in grapes and wine, is considered a potential cancer chemopreventive agent. Resveratrol has been shown to induce transcription via both ERalpha and ERbeta. We observed significantly lower tumor growth, decreased angiogenesis, and increased apoptotic index in ERalpha- ERbeta+ MDA-MB-231 tumors in resveratrol-treated nude mice compared with controls. In vitro we found a significant increase in apoptosis in resveratrol-treated MDA-MB-231 cells in addition to significantly reduced extracellular levels of VEGF. This study supports the potential use of resveratrol as a chemotherapeutic agent in breast cancers.

[1]  C. Dabrosin.  Variability of vascular endothelial growth factor in normal human breast tissue in vivo during the menstrual cycle. , 2003, The Journal of clinical endocrinology and metabolism.

[2]  Jack Gauldie,et al.  Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer , 2003, International journal of cancer.

[3]  Anthony J. Guidi,et al.  Vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[5]  U. Brunk,et al.  Visualization of iron in cultured macrophages: a cytochemical light and electron microscopic study using autometallography. , 1993, Free radical biology & medicine.

[6]  E. Wynder,et al.  International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption , 1986 .

[7]  Yihai Cao,et al.  Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  R. Collins,et al.  Ovarian ablation in early breast cancer: overview of the randomised trials , 1996, The Lancet.

[9]  J. Folkman,et al.  Tumor growth and neovascularization: an experimental model using the rabbit cornea. , 1974, Journal of the National Cancer Institute.

[10]  J. Pezzuto,et al.  Cancer Chemopreventive Activity of Resveratrol , 2002, Drugs under experimental and clinical research.

[11]  D. Coradini,et al.  Hypoxia and estrogen receptor profile influence the responsiveness of human breast cancer cells to estradiol and antiestrogens , 2003, Cellular and Molecular Life Sciences CMLS.

[12]  S. Mulero-Navarro,et al.  The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. , 2002, Biochemical pharmacology.

[13]  D. Shapiro,et al.  Estrogen Receptor-dependent and Estrogen Receptor-independent Pathways for Tamoxifen and 4-Hydroxytamoxifen-induced Programmed Cell Death* , 2002, The Journal of Biological Chemistry.

[14]  L L Vindeløv,et al.  A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. , 1990, Cytometry.

[15]  J. Ashby,et al.  Partial and weak oestrogenicity of the red wine constituent resveratrol: consideration of its superagonist activity in MCF‐7 cells and its suggested cardiovascular protective effects , 1999, Journal of applied toxicology : JAT.

[16]  J. Pezzuto,et al.  Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. , 2001, Cancer research.

[17]  J. Jameson,et al.  Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[19]  B. Modan,et al.  Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. , 1990, Journal of the National Cancer Institute.

[20]  S. Kulp,et al.  Estrogenic down-regulation of protein tyrosine phosphatase gamma (PTP gamma) in human breast is associated with estrogen receptor alpha. , 2002, Anticancer research.

[21]  G. Mor,et al.  Estrogen-regulated developmental neuronal apoptosis is determined by estrogen receptor subtype and the Fas/Fas ligand system. , 2000, Journal of neurobiology.

[22]  C. Klinge,et al.  Resveratrol Acts as a Mixed Agonist / Antagonist for Estrogen Receptors a and b * , 2000 .

[23]  J. Le Bail,et al.  Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. , 2000, Life sciences.

[24]  R. Henriksson,et al.  Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Shaw,et al.  Advances in Brief Vascular Endothelial Growth Factor Is an Autocrine Survival Factor for Neuropilin-expressing Breast Carcinoma Cells 1 , 2001 .

[26]  C. Dabrosin,et al.  Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. , 2002, Cancer letters.

[27]  J. Gustafsson,et al.  A Role for the Androgen Receptor in Follicular Atresia of Estrogen Receptor Beta Knockout Mouse Ovary1 , 2002, Biology of reproduction.

[28]  Julie Morris,et al.  Assessment of Vascularity in Histological Sections: Effects of Methodology and Value as an Index of Angiogenesis in Breast Tumours , 1998, The Histochemical Journal.

[29]  G. Serrero,et al.  Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells , 1999, Journal of cellular physiology.

[30]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[31]  M. Karkkainen,et al.  Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells , 1999, Molecular and Cellular Endocrinology.

[32]  H. Adlercreutz,et al.  Dietary phytoestrogens and cancer: in vitro and in vivo studies , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[33]  Á. Tósaki,et al.  Benefits of resveratrol in women's health. , 2001, Drugs under experimental and clinical research.

[34]  C. Dabrosin,et al.  Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. , 2003, Cancer research.

[35]  A. Maran,et al.  Is Resveratrol an Estrogen Agonist in Growing Rats?* *This work was supported by NIH Grant AA-11140 and the Mayo Foundation. , 1999, Endocrinology.

[36]  G. Núñez,et al.  Caspases: the proteases of the apoptotic pathway , 1998, Oncogene.

[37]  J. Lakins,et al.  Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. , 2000, Oncology reports.

[38]  Patricia A. Dyck,et al.  Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. , 2002, Cancer research.

[39]  R C Coombes,et al.  Estrogen receptor beta in breast cancer. , 2002, Endocrine-related cancer.

[40]  A. El-Mowafy,et al.  Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. , 2003, Carcinogenesis.

[41]  J. Casida,et al.  Anticancer action of cubé insecticide: correlation for rotenoid constituents between inhibition of NADH:ubiquinone oxidoreductase and induced ornithine decarboxylase activities. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  D. Gomez,et al.  Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. , 1996, Cancer research.

[43]  R. Snapka,et al.  DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. , 1998, Journal of natural products.

[44]  J. Russo,et al.  Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. , 1998, International journal of oncology.

[45]  R. Henriksson,et al.  Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  L. Moore,et al.  Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. , 1999, Cancer research.

[47]  Norman R. Farnsworth,et al.  Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes , 1997, Science.

[48]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.